(BTMD) Actualités

Form SC TO-C - Written communication relating to an issuer or third party

Form SC14D9C - Written communication relating to third party tender offer

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Revance Therapeutics, Inc.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Revance Therapeutics, Inc. PR Newswire NEW YORK, Aug. 12, 2024 NEW YORK, Aug. 12...

Form 8-K - Current report

Crown Laboratories and Revance Announce Entry Into Merger Agreement

Crown Laboratories and Revance Announce Entry Into Merger Agreement PR Newswire JOHNSON CITY, Tenn. and...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Revance Reports Second Quarter 2024 Financial Results, Provides Corporate Update

- Q2 total DAXXIFY® and RHA® (by Teoxane SA) product revenue of $65.3 million, a YoY increase of 20%. - Q2 DAXXIFY net revenue of $28.7 million...

Revance to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Conference Call Scheduled for Thursday, August 8, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (NASDAQ: RVNC) today announced that the...

Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced new hire grants totaling an aggregate of 104,800 inducement restricted stock units...

Revance to Participate in Upcoming Investor Conferences

Revance Therapeutics, Inc. (NASDAQ: RVNC) today announced that the company will be participating in the following investor conferences. William...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update

- Total net product revenue (DAXXIFY® and RHA® Collection) of $51.7 million, a YoY increase of 13%. - DAXXIFY® net revenue of $22.1 million...